Kalehua Capital Management LLC's Q1 2026 13F: 9 new positions, 3 exits
Form 13F-HR for the quarter ended Mar 31, 2026 · filed May 15, 2026 · 25 reported positions · accession 0002106181-26-000004 · Amended
What changed this quarter
| Activity | Security | Weight before | Weight now | Change | Shares | Shares % |
|---|---|---|---|---|---|---|
| New | VERADERMICS INC (MANE) | — | 6.5% | +6.5 pts | +146K sh | new |
| New | ACLARIS THERAPEUTICS INC (ACRS) | — | 4.9% | +4.9 pts | +1.83M sh | new |
| Exited | Allogene Therapeutics Inc (ALLO) | 3.5% | — | −3.5 pts | −2.55M sh | −100% |
| New | Uniqure NV (QURE) | — | 3.4% | +3.4 pts | +291K sh | new |
| New | Damora Therapeutics Inc (GLTO) | — | 2.5% | +2.5 pts | +139K sh | new |
| Increased | Inhibikase Therapeutics Inc (IKT) | 3.5% | 4.5% | +1.0 pts | +2.07M sh | +118% |
| New | Gossamer Bio Inc (GOSS) | — | 2.4% | +2.4 pts | +10.24M sh | new |
| Exited | Oric Pharmaceuticals Inc (ORIC) | 2.2% | — | −2.2 pts | −267K sh | −100% |
| Exited | Verrica Pharmaceuticals Inc (VRCA) | 1.9% | — | −1.9 pts | −236K sh | −100% |
| New | PepGen Inc (PEPG) | — | 1.3% | +1.3 pts | +1M sh | new |
| New | Instil Bio Inc (TIL) | — | 1.1% | +1.1 pts | +183K sh | new |
| Reduced | EA SERIES TRUST (BOXX) | 26.3% | 18.0% | −8.3 pts | −12,509 sh | −5% |
| New | KORRO BIO INC (KRRO) | — | 0.9% | +0.9 pts | +109K sh | new |
| New | LONGEVERON INC (LOOP) | — | 0.3% | +0.3 pts | +348K sh | new |
| Reduced | DiaMedica Therapeutics Inc (DMAC) | 0.8% | 0.3% | −0.5 pts | −32,871 sh | −34% |
| Reduced | Kalaris Therapeutics Inc (KLRS) | 1.2% | 0.6% | −0.6 pts | −4,316 sh | −3% |
Reported by the fund in its Form 13F filed with the SEC; holdings are as of the quarter-end report date and may have changed since. For informational purposes only — not investment advice or a recommendation to buy or sell any security. FilingExplorer is not affiliated with or endorsed by this fund. How this brief is compiled
Top 10 positions — 72.7% of the equity book
Changes in the top 10 this quarter: SRZN entered · MANE entered · ACRS entered · CMPS left · SEPN left · ALLO left
| # | Security | Weight before | Weight now | |
|---|---|---|---|---|
| 1 | EA SERIES TRUST (BOXX) | 26.3% | 18.0% | |
| 2 | X4 Pharmaceuticals Inc (XFOR) | 14.7% | 10.9% | |
| 3 | Surrozen Inc (SRZN) | 1.9% | 7.9% | Entered the top 10 |
| 4 | VERADERMICS INC (MANE) | 0.0% | 6.5% | Entered the top 10 |
| 5 | Relay Therapeutics Inc (RLAY) | 7.5% | 6.3% | |
| 6 | Sionna Therapeutics Inc (SION) | 8.0% | 5.6% | |
| 7 | ACLARIS THERAPEUTICS INC (ACRS) | 0.0% | 4.9% | Entered the top 10 |
| 8 | Inhibikase Therapeutics Inc (IKT) | 3.5% | 4.5% | |
| 9 | Oruka Therapeutics Inc (ORKA) | 3.6% | 4.1% | |
| 10 | Pharvaris NV (PHVS) | 5.5% | 4.0% | |
| — | Compass Pathways PLC (CMPS) | 5.6% | 3.2% | Left the top 10 |
| — | Septerna Inc (SEPN) | 5.4% | 3.3% | Left the top 10 |
| — | Allogene Therapeutics Inc (ALLO) | 3.5% | 0.0% | Left the top 10 |
Weights are each position's reported value as a share of the fund's reported equity positions (options and principal-amount holdings excluded).